Stifel analyst Benjamin Burnett raised the firm’s price target on Disc Medicine to $104 from $76 and keeps a Buy rating on the shares ahead of the AURORA trial readout and into three additional DISC-0974 readouts later this year. The firm is “optimistic” on AURORA and also thinks myelofibrosis data are trending well, making it more constructive on DISC-0974’s “best-in-class potential,” the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IRON:
- Disc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024
- Disc Medicine price target raised to $80 from $70 at BMO Capital
- Disc Medicine Appoints New CCO With Inducement Grant
- Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as Chief Commercial Officer
- Disc Medicine appoints Pamela Stephenson as CCO
